Pharmaceutical liquid crystals: The relevance of partially ordered systems

Journal of Pharmaceutical Sciences

Volumn 94, Issue 9, 2005, Pages 1861-1880

  Stevenson, Cynthia L ^a   Bennett, David B ^a   Lechuga Ballesteros, David ^a  

^a NEKTAR THERAPEUTICS   (United States)

Author keywords

Fibril; Liquid crystal; Lyotropic; Mesophase; Nematic; Protein; Review; Thermotropic

Indexed keywords

ACTIN; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ARSPHENAMINE; CALCITONIN; COLLAGEN; CROMOGLYCATE DISODIUM; CYCLOSPORIN A; DICLOFENAC; FENOPROFEN; FLUFENAMIC ACID; FOLIC ACID; ITRACONAZOLE; KETOPROFEN; LEUPRORELIN; METHOTREXATE; NAFCILLIN; NAFOXIDINE; POLYGLUTAMIC ACID; POLYLYSINE; PROTEIN; SILK FIBROIN; SOLVENT; TOBRAMYCIN; UNINDEXED DRUG; VERLUKAST; VITAMIN;

ATOMIC FORCE MICROSCOPY; BIREFRINGENCE; DIABETES MELLITUS; DIFFERENTIAL SCANNING CALORIMETRY; EMULSION; HUMAN; LIQUID CRYSTAL; MICELLE; MICROSCOPY; MOLECULAR SIZE; OSTEOPOROSIS; PHARMACEUTICS; SHORT SURVEY; TEMPERATURE; THERMOGRAVIMETRY; WATER CONTENT; X RAY CRYSTALLOGRAPHY; X RAY POWDER DIFFRACTION;

EID: 27644552573     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20435     Document Type: Review

References (113)

1. Rodríguez-Hornedo N, Murphy D. 1999. Significance of controlling crystallization mechanism and kinetics in pharmaceutical systems. J Pharm Sci 88:651-660.
2. Fleischman S, Morales L, Moulton B, Rodríguez-Hornedo N, Bailey Walsh R, Zaworotko MJ. 2002. Crystal engineering of the composition of pharmaceutical phases. Chem Commun 3:186-187.
3. Fleischman SG, Kuduva SS, McMahon JA, Moulton B, Walsh B, Rosa D, Rodríguez-Hornedo N, Zaworotko MJ. 2003. Crystal engineering of the composition of pharmaceutical phases: Multiple-component crystalline solids involving carbamazepine. Crystal Growth Design 3:909-919.
4. Haleblian J, McCrone W. 1969. Pharmaceutical applications of polymorphism. J Pharm Sci 58: 911-929.
5. Haleblian JK. 1975. Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J Pharm Sci 64: 1269-1288.
6. Grant DJW. 1999. Theory and origin of polymorphism. In: Brittain HG, editor. Polymorphism in pharmaceutical solids. New York: Marcel Dekker Inc.
7. Desiraju G. 1997. Crystal gazing: Structure prediction and polymorphism. Science 278:404-405.
8. Ahlneck C, Zografi G. 1990. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int J Pharm 62:87-95.
9. Hancock BC, Shamblin SL, Zografi G. 1995. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res 12:799-806.
10. Oksanen CA, Zografi G. 1990. The relationship between the glass transition temperature and water vapor absorption by poly(vinylpyrrolidone). Pharm Res 7:654-657.
11. Pikal MJ. 1999. Mechanisms of protein stabilization during freeze-drying and storage: The relative importance of thermodynamic stabilization and glassy state relaxation dynamics. In: Rey L, May JC, Sarbrick J, editors. Freeze-drying/lyophilization of pharmaceutical and biological products, drugs and the pharmaceutical sciences, Vol. 96. New York: Marcel Dekker. pp 161-198.
12. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
13. Leuner C, Dressman J. 2000. Improving drug Solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47-60.
14. Wunderlich B. 1999. A classification of molecules, phases and transitions as recognized by thermal analysis. Thermochimica Acta 340:37-52.
15. Brown GH. 1972. Liquid crystals and their roles in inanimate and animate systems. Am Scientist 60:64-73.
16. Brown GH, Crooker PP. 1983. Liquid crystals a colorful state of matter. C&EN 24-38.
17. Chandrasekhar S. 1992. Liquid crystals. Cambridge: Cambridge University Press.
18. Rades T, Muller-Goymann CC. 1994. Melting behavior and thermotropic mesomorphism of fenoprofen salts. Eur J Pharm Biopharm 40: 277-282.
19. Rades T, Padmadisastra Y, Muller-Goymann CC. 1996. Thermal Behavior and solubility of fenoprofen calcium. Pharmazie 51:846-851.
20. Rades T, Muller-Goymann CC. 1992. Structural investigations on the liquid crystalline phases of fenoprofen. Pharmacol Biochem Prop Drug Sust 2:131-134.
21. Hamann HJ, Muller-Goymann CC. 1987. Lyotroper Mesoprophismus von Arneistoffen unter besonderer Berucksichtigung der Profene. Acta Pharm Technol 33:67-73.
22. Mlodozeniec AR. 1978. Thermodynamics and physical properties of a lyotropic mesophase (liquid crystal) and micellar solution of an ionic amphiphile. J Soc Cosmet Chem 29:659-683.
23. Vadas E, Toma P, Zografi G. 1991. Solid state phase transitions initiated by water vapor sorption of crystalline L-660-711, a leukotriene D4 receptor antagonist. Pharm Res 8:148-155.
24. Saez IM, Benvegnu T, Tuffin RP, Goodby JW, Plusquellec D, Mehl GH, AuzEly-Velty R, MacKenzie G. 1998. Liquid crystals with restricted molecular topologies: Supermolecules and supramolecular assemblies. Chem Commun 998:2057-2070.
25. Valluzzi R, He SJ, Gido SP, Kaplan D. 1999. Bombyx mori silk fibroin liquid crystal and crystallization at aqueous fibroin-organic solvent interfaces. Int J Biol Macromolecules 24:227-236.
26. He SJ, Valluzzi R, Gido SP. 1999. Silk I structure in Bombyx mori silk foams. Int J Biol Macromolecules 24:187-195.
27. Wilson D, Valluzzi R, Kaplan D. 2000. Conformations transitions in model silk peptides. Biophys J 78:2690-2701.
28. Subramanian R, DuPre DB. 1984. Phase transitions and polypeptide liquid crystals: (T, Φ) phase diagram including the reentrant isotropic phase. J Chem Phys 81:4626-4629.
29. Patel DL, DuPre DB. 1980. Optical rotary behavior of polypeptide solutions in the liquid crystal and pretranslational regions. J Chem Phys 72: 2515-2524.
30. DuPre DB, Yang SJ. 1991. Liquid crystalline properties of solutions of persistent polymer chains. J Chem Phys 94:7466-7477.
31. Valluzzi R, Kaplan DL. 2000. Sequence specific liquid crystallinity of collagen model peptides. I. Transmission electron microscopy studies of interfacial collagen gels. Biopolymers 53:350-362.
32. Zakharova SS, Jess W, Backendorf C, van der Maarel JRC. 2002. Liquid crystal formation in supercoiled DNA solutions. Biophys J 83:1119-1129.
33. Adams M, Fraden S. 1998. Phase behavior of mixtures of rods (tobacco mosaic virus) and spheres (polyethylene oxide, bovine serum albumin). Biophys J 74:669-677.
34. Diaz-Avalos R, Casper DLD. 1998. Structure of the stacked disk aggregate of tobacco mosaic virus protein. Biophys J 74:595-603.
35. Forood B, Perez-Paya E, Houghten RA, Blondelle SE. 1995. Formation of an extremely stable polyalanine β-sheet macromolecule. Biochem Biophys Res Commun 211:7-13.
36. Suzuki A, Maeda T, Ito T. 1991. Formation of liquid crystalline phase of actin filament solutions and its dependence on filament length as studied by optical birefringence. Biophys J 59:25-30.
37. Coppin CM, Leavis PC. 1992. Quantitation of liquid crystalline ordering in F-actin solutions. Biophys J 63:794-807.
38. Gallot B, Fafiotte M, Fissi A, Pieroni O. 1997. Poly(L-lysine) containing azobenzene units in the side chains: Influence of the degree of substitution on liquid crystalline structure and thermotropic behavior. Liquid Crystals 23:137-146.
39. Okoshi K, Sano N, Suzki G, Tokita M, Watanabe J, Magshi J. 2002. Smectic liquid crystal observed in thermotropic system of rigid-rod poly (GAMA-octadecyl L-glutamate). Jpn J Appl Phys Part 241: L720-L722.
40. McMillan RA, Wright ER, Conicello VP. 2001. Elastin-mimetic protein polymers: Biologically derived smart materials. Smart Structures and Materials 2001: Industrial and Commercial Applications of Smart Structure Technologies, SPIE International Society for Optical Engineering, 439-454.
41. Zhu H, Xu J, Varlashkin P, Long S, Kidd C. 2001. Dehydration, hydration behavior and structural analysis of fenoprofen calcium. J Pharm Sci 90: 845-859.
42. Rades T, Muller-Goymann CC. 1997. Electron and light microscopical investigation of defect structures in mesophases of pharmaceutical substances. Coll Polym Sci 275:1169-1178.
43. Patterson J, Bary A, Rades T. 1992. Physical stability and solubility of the thermotropic mesophase of fenoprofen calcium as pure drug and in a tablet formulation. Int J Pharm 247:147-157.
44. Stephenson GA, Diseroad BA. 2000. Structural relationship and desolvation behavior of cromolyn, cefazolin and fenoprofen sodium hydrates. Int J Pharm 198:167-177.
45. Six K, Berghmans H, Leuner C, Dressman J, Van Werde K, Mullens J, Benoist L, Thimon M, Meublat L, Verreck G, Peeters J, Brewster M, Van den Mooter G. 2003. Characterization of solid dispersions of itraconazole and hydroxypropyl-methylcellulose prepared by melt extrusion, part II. Pharm Res 20:1047-1054.
46. Six K, Verreck G, Peeters J, Augustijns P, Kinget R, Van den Mooter G. 2001. Investigation of thermal properties of glassy itraconazole: Identification of a monotropic mesophase. Thermchim Acta 376:175-181.
47. Bogardus JB. 1982. Phase equilibria of nafcillin sodium-water. J Pharm Sci 71:105-109.
48. Milton N, Nail SL. 1996. The physical state of nafcillin sodium in frozen aqueous solutions and freeze-dried powders. Pharm Dev Technol 1:269-277.
49. Lechuga-Ballesteros D, Abdul-Fattah A, Liang Y, Miller D, Stevenson CL, Zhang J, Bennett DB. 2004. Liquid crystallinity improves the physical stability of spray dried particles for inhalation. In: Dalby RN, Byron PR, Farr SJ, Peart J, editors. Respiratory drug delivery IX. Palm Springs, CA: Serentec Press, Inc.
50. Chan HK, Gonda I. 1991. Methotrexate: Existence of different types of solid. Int J Pharm 68: 179-190.
51. Abdul-Fatta A, Zhang J, Bennett DB, Ballesteros-Lechuga D. 2003. Characterization of spray-dried powders in the liquid crystalline state. Pharm Sci 4:M1286.
52. Cox JSG, Woodard GD, McCrone WC. 1971. Solid state chemistry of cromolyn sodium (disodium cromoglycate). J Pharm Sci 60:1453-1465.
53. Hartshorne NH, Woodard GD. 1973. Mesomorphism in the system disodium chromoglycate-water. Mol Crystals Liquid Crystals 23:343-368.
54. Chen LR, Young VG Jr, Lechuga-Ballesteros D, Grant DJW. 1999. Solid state behavior of cromolyn sodium hydrates. J Pharm Sci 88:1191-1200.
55. Ciuchi F, Nicola GD, Franz H, Gottarelli G, Mariani P, Bossi MGP, Spada GP. 1994. Self-recognition and self-assembly of folic acid salts: Columnar liquid crystalline polymorphism and the column growth process. J Am Chem Soc 116: 7064-7071.
56. Igimi H, Nishijima S, Shimura H. 1983. The developmental process from micelle to liquid crystal in the ursodeoxycholate, phosphatidylcholine and cholesterol solution. J Pharm Dyn 6:267-271.
57. Kanie K, Nishii M, Yasuda T, Taki T, Ujiie S, Kato T. 2001. Self-assembly of thermotropic liquid crystalline folic acid derivatives: Hydrogen-bonded complexes forming layers and columns. J Mater Chem 11:2875-2886.
58. Kanie K, Yasuda T, Ujiie S, Kato T. 2000. Thermotropic liquid crystalline folic acid derivatives: Supramolecular discotic and smectic aggregation. Chem Commun 1899-1900.
59. Ueno Y, Yonemochi E, Tozuka Y, Yamamura S, Oguchi T, Yamamoto K. 1998. Characterization of amorphous ursodeoxycholic acid by spray drying. J Pharm Pharmacol 50:1213-1219.
60. Yonemochi E, Ueno Y, Ohmae T, Oguchi T, Nakajima SI, Yamamoto K. 1997. Evaluation of amorphous ursodeoxycholic acid by thermal methods. Pharm Res 14:798-803.
61. Yonemochi E, Oda K, Saeki S, Oguchi T, Nakai Y, Yamamoto K. 1994. Physicochemical properties of amorphous ursodeoxycholic acid obtained by grinding. Chem Pharm Bull 42:1948-1950.
62. Yonemochi E, Ueno Y, Buckton G, Moffat A, Oguchi T, Yamamoto K. 1999. Differences in crystallization behavior between quenched and ground amorphous ursodeoxycholic acid. Pharm Res 16:835-840.
63. Nestor J Jr, Ho T, Simpson RA, Horner BL, Jones GH, McRae GI, Vicery BH. 1982. Synthesis and biological activity of some very hydrophobic superagonist analogs of luteinizing hormone releasing hormone. J Med Chem 25:795-801.
64. Powell MF, Sanders LM, Rogerson A, Si V. 1991. Parenteral Peptide formulations: Chemical and physical properties of native luteinizing hormone-releasing hormone (LHRH) and hydrophobic analogues in aqueous solution. Pharm Res 8: 1258-1263.
65. Powell ME, Fleitman J, Sanders LM, Si VC. 1994. Peptide liquid crystals: Inverse correlation of kinetic formation and thermodynamic stability in aqueous solution. Pharm Res 11:1352-1354.
66. Tan MM, Corley CA, Stevenson CL. 1998. Effect of gelation on the chemical stability and conformation of leuprolide. Pharm Res 15:1442-1448.
67. Samulski ET, DuPre DB. 1983. Lyotropic polymeric liquid crystals. J Chim Physique 80:25-30.
68. Nikiforovich GV, Marshall GR. 1993. Conformation-function relationships in LHRH analogs II. Conformations of LHRH peptide agonists and antagonists. Int J Peptide Protein Res 42:181-193.
69. Keenan RJ, Iacono A, Dauber JH, Zeevi A, Adriana SA, Ohori NP, Burchat GJ, Dawai A, Smaldone GC, Griffith BP. 1997. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg 113:335-341.
70. Smaldone GC. Treatment of transplant rejection by aerosolized cyclosporine. In: Dalby RN, Byron P, Farr JS, editors. Respiratory drug delivery VI. Buffalo, NY: Interpharm Press, Inc. 103-111.
71. Loosli HR, Kessler H, Oschkinat H, Weber HP, Petcher T, Wider A. 1985. The conformation of cyclosporin A in the crystal and in solution. Helvetica Chimica Acta 68:682-703.
72. Lechuga-Ballesteros D, Abdul-Fattah A, Stevenson CL, Bennett D. 2003. Properties and stability of a liquid crystal form of cyclosporine-the first reported naturally occurring peptide that exists as a thermotropic liquid crystal. J Pharm Sci 92: 1821-1831.
73. Bennett D, Cabot K, Foster L, Lechuga-Ballesteros D, Tan T. 1999. Liquid crystal forms of cyclosporin. US Patent Application 990352, WO 99/42124.
74. Lechuga-Ballesteros D, Bennett D, Cabot K, Farinas K, Gong D, Hastedt J, Ramanathan S, Tan T, Venthoye G, Williams L, Wang M. 2000. Aerosol drug development of a spray dried liquid crystalline formulation of cyclosporine. Respiratory Drug Delivery VII 247-255.
75. Johari GP, Goodby JW. 1982. Dielectric relaxation in a supercooled liquid and glassy smectic phase. J Chem Phys 77:5165-5172.
76. Chen W, Toda A, Moon IK, Wunderlich B. 1999. Analysis of transitions of liquid crystals and conformationally disordered crystals by temperature modulated calorimetry. J Polym Sci Part B: Polym Phys 37:1539-1544.
77. Giron D, List M, Richter F, Ulke Y, Weber HP. 1989. New Cyclosporin crystal form, process for its production, pharmaceutical compositions containing it and its use. Sandoz Patent DE 3843054 A1.
78. Ko SY, Dalvit C. 1992. Conformation of cyclosporin A in polar solvents. Int J Peptide Protein Res 40:380-382.
79. Verheyden P, Jaspers H, Wolf E, Van Binst G. 1994. Conformational study of cyclosporin A in acetone at low temperature. Int J Peptide Protein Res 44:364-371.
80. 6 by a combination of homo and heteronuclear two-dimensional techniques. Helv Chim Acta 68:661-681.
81. Petcher TJ, Weber HP, Ruegger A. 1976. Crystal and molecular structure on an iodo-derivative of the cyclic undecapeptide cyclosporin A. Helv Chim Acta 59:1480-1489.
82. Stevenson CL, Tan MM, Ballesteros-Lechuga D. 2003. Secondary structure of cyclosporine spray dried liquid crystal by FTIR. J Pharm Sci 92: 1832-1843.
83. Bauer HH, Muller M, Goette J, Merkle HP, Fringeli UP. 1994. Interfacial adsorption and aggregation associated changes in secondary structure of human calcitonin monitored by ATR-FTIR spectroscopy. Biochemistry 33: 12276-12282.
84. Stevenson CL, Tan MM. 2000. Solution stability of salmon calcitonin at high concentration for delivery in an implantable system. J Peptide Res 55:129-139.
85. Arvinte T, Cudd A, Drake AF. 1993. The structure and mechanism of formation of human calcitonin fibrils. J Biol Chem 268:6415-6422.
86. Gilchrist PJ, Bradshaw JP. 1993. Amyloid formation by salmon calcitonin. Biochim Biophys Acta 1182:111-114.
87. Cudd A, Arvinte T, Ganes Das RE, Chinni C, MacIntyre I. 1995. Enhanced potency of human calcitonin when fibrillation is avoided. J Pharm Sci 84:717-719.
88. Arvinte T, Drake AF. 1993. Comparative study of human and salmon calcitonin secondary structure in solutions with low dielectric constants. J Biol Chem 268:6408-6414.
89. Kanaori K, Nosaka AY. 1995. Study of human calcitonin fibrillation by proton nuclear magnetic resonance spectroscopy. Biochemistry 34:12138-12143.
90. Motta A, Pastore A, Goud NA, Castiglione Morelli NA. 1991. Solution conformation of salmon calcitonin in sodium dodecyl sulfate micelles as determined by two-dimensional NMR and distance geometry calculations. Biochemistry 30: 10444-10450.
91. Motta A, Anderotti G, Amodeo P, Strazzullo G, Castiglione Morelli MA. Solution structure of human calcitonin in membrane-mimetic environments: The role of the amphipathic helix. Proteins Struct Func Genet 32:314-323.
92. Kanaori K, Nosaka AY. 1996. Characterization of human calcitonin fibrillation in aqueous urea solution by 1H NMR spectroscopy. Biochemistry 35:12671-12676.
93. Moriarty DF, Vagts S, Raleigh DP. 1998. A role for the C-terminus of calcitonin in aggregation and gel formation: A comparative study of C-terminal fragments of human and salmon calcitonin. Biochem Biophys Res Commun 245:344-348.
94. Goldsbury C, Kistler J, Aebi U, Arvinte T, Cooper GJS. 1999. Watching amyloid fibrils grow by time lapse atomic force microscopy. J Mol Biol 285: 33-39.
95. Hekman C, DeMond W, Dixit T, Mauch S, Nuechterlein M, Stepanenko A, Williams JD, Ye M. 1998. Isolation and identification of peptide degradation products of heat stressed pramlinitide injection drug product. Pharm Res 15:650-659.
96. Baeur HH, Aebi U, Haener M, Hermann R, Meuller M, Arvinte T, Merkle HP. 1995. Architecture and polymorphism of fibrillar supramolecular assemblies produced by in vitro aggregation of human calcitonin. J Struct Biol 115:1-15.
97. Shen CL, Scott GL, Merchant F, Murphy RM. 1993. Light scattering analysis of fibril growth from the amino-terminal fragment β(1-28) of β-amyloid peptide. Biophys J 65:2383-2395.
98. Wille H, Zhang GF, Baldwin MA, Cohen FE, Prusiner SB. 1996. Separation of scrapie prion infectivity from PrP amyloid polymers. J Mol Biol 259:608-621.
99. Benvenga S, Trimarchi F, Facchiano A. 1994. Homology of calcitonin with the amyloid-related proteins. J Endocrinol Invest 17:119-122.
100. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM. 1987. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628-8632.
101. Soto C, Castano EM. 1996. The conformation of Alzheimer's β-peptide determines the rate of amyloid formation and its resistance to proteolysis. Biochem J 314:701-707.
102. Terzi E, Holzemann G, Seelig J. 1995. Self-association of β-amyloid peptide (1-40) in solution and binding to lipid membranes. J Mol Biol 252: 633-642.
103. Terzi E, Holzemann B, Seelig I. 1996. Reversible random coil-β-sheet transition of the Alzheimer β-amyloid fragments (25-35). Biochemistry 33: 1345-1350.
104. Lomakin A, Chung DS, Benedek GB, Kirschner DA, Teplow DB. 1996. On the nucleation and growth of amyloid β-protein fibrils: Detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci USA 93:1125-1129.
105. Jarrett JT, Berger EP, Lansbury PT Jr. 1993. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697.
106. Kim YS, Randolph TW, Manning MC, Stevens FJ, Carpenter JF. 2003. Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation. J Biol Chem 278:10842-10850.
107. 2. Arch Biochem Biophys 335:381-387.
108. Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG. 1996. Nicotine inhibits amyloid formation by the β-peptide. Biochemistry 35: 13568-13578.
109. Schulke U. 1987. Synthese und Untersuchung von flussigkristallinen, semiflexiblen Hauptkettenpolymeren. Thesis, Technical University of Darmstadt, Germany.
110. Kuntsche J, Westesen K, Drechsler M, Koch MHJ, Bunjes H. 2004. Supercooled smectic nanoparticles-a potential novel carrier system for poorly water soluble drugs. Pharm Res 21:1836-1845.
111. Nesseem DI. 2001. Formulation and evaluation of itraconazole via liquid crystal for topical delivery system. J Pharm Biomed Analysis 26:387-399.
112. Bennett DB, Tyson E, Mah S, deGroot JS, Hegde SG, Terao S, Teitelbaum Z. 1994. Sustained delivery of detirelix after pulmonary administration of liposomal formulations. J Contr Rel 32:27-35.
113. Bennett DB, Tyson E, Nerenberg CA, Mah S, deGroot JS, Teitelbaum Z. 1994. Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly anesthetized dog. Pharm Res 11:1048-1055.